

## **SPEAKER BIOGRAPHIES**

### **21st Century Cancer Care: Will New Models Lead to Better Care at Lower Cost?**

November 7, 2014

**NANCY E DAVIDSON** is the director of the University of Pittsburgh Cancer Institute and UPMC CancerCenter and Hillman Professor of Oncology at the University of Pittsburgh. An international expert in breast cancer biology and treatment and practicing medical oncologist, Dr. Davidson has published key findings on the role of hormones, particularly estrogen, on gene expression and cell growth in breast cancer. She has guided several important national clinical trials of potential new therapies, including chemoendocrine therapy for premenopausal breast cancer and optimal adjuvant chemotherapy. Dr. Davidson received her bachelor's degree from Wellesley College and medical degree from Harvard Medical School. She completed a residency in internal medicine at Johns Hopkins Hospital and a fellowship at the National Cancer Institute. Dr. Davidson recently served as president of the American Society of Clinical Oncology and initiated the Value in Cancer Care Task Force during her term. She serves as a member of the scientific advisory board of numerous cancer centers in the US and abroad as well as several foundations. She is a member of the Institute of Medicine of the National Academies and Association of American Physicians.

**SHELLEY FULD NASSO** is chief executive officer of the National Coalition for Cancer Survivorship. She serves as a member of the National Cancer Institute's National Council of Research Advisors and the American Society of Clinical Oncology's Cancer Survivorship Committee. Prior to joining NCCS, Ms. Fuld Nasso served in leadership roles at Susan G. Komen, where she leveraged the strength of Komen's grassroots network to strengthen the organization's reputation and visibility in Washington, D.C., and in state capitals. Ms. Fuld Nasso has also served as Director of Community Philanthropy at The Dallas Foundation and held management positions at communications and technology enterprises. Her commitment to the work of NCCS is strongly tied to the experiences in the cancer care system of her dear friend, Dr. Brent Whitworth, a beloved physician diagnosed with stage IV cancer days before his 42nd birthday. Through Dr. Whitworth's battle, Ms. Fuld Nasso witnessed the strengths and flaws of the cancer care system and embraces the notion that policy change can directly benefit patients and caregivers going through this journey. She is a graduate of Rice University and holds a Master of Public Policy from the Harvard Kennedy School.

(over)

**JENNIFER MALIN** is the medical director for Oncology Solutions and Innovation at WellPoint, Inc. In this role, she provides clinical leadership for all aspects of the delivery of care for WellPoint members with cancer. She holds as Associate Professor of Medicine at the UCLA David Geffen School of Medicine, and she is the author of more than 70 peer-reviewed articles and is widely recognized for her research on the quality of cancer care. Dr. Malin has served on a number of advisory boards and national committees including the American Society of Clinical Oncology's Quality of Care Committee and the National Quality Forum's Cancer Steering Committee. She is a graduate from Harvard University, and received her medical degree and doctorate in public health from UCLA. She is board certified in internal medicine and medical oncology. Dr. Malin is a practicing medical oncologist, and continues her clinical practice by volunteering at the Veterans Affairs Greater Los Angeles Health Care System.

**DEBORAH SCHRAG** is medical oncologist and a health services researcher at the Dana-Farber Cancer Institute. She is Chief of the Division of Population Sciences and a Professor of Medicine at Harvard Medical School. Dr. Schrag is a practicing clinician with longstanding focus on gastrointestinal cancer, particularly colorectal cancer. She leads the only publicly funded NCI-sponsored nationwide clinical trial in rectal cancer and works with investigators across the country to advance innovation in cancer therapeutics. Broadly, her work focuses on optimizing the quality and effectiveness of cancer care delivery systems to ensure that innovations in cancer medicine realize their full potential by reaching all communities and populations. Among her many roles, Dr. Schrag has served as a Director of the Board of Internal Medicine, a Board Member of ASCO and as a member of the National Cancer Policy Forum. Her work is funded by NCI, AHRQ, and PCORI.